Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Solvay Pharmaceuticals

Criteria

Inclusion Criteria:

• sitting office diastolic blood pressure between 90 and 109 mmHg

• office systolic blood pressure between 140 and 179 mmHg

• mean day-time diastolic 24-h ABPM blood pressure >= 85 mmHg inclusive at baseline

Exclusion Criteria:

• known secondary hypertension

• decompensated congestive heart failure